Treatment of HCV/HIV coinfection with leukocyte derived interferon alfa-n3.

被引：0
|
作者：
Sherman, KE
Lalezari, J
Brand, JD
Yoffe, B
Yangco, B
Fedorczyk, D
机构：
[1] Univ Cincinnati, Coll Med, Cincinnati, OH USA
[2] Quest Clin Res, San Francisco, CA USA
[3] Oaklawn Physicians, Dallas, TX USA
[4] Baylor Coll Med, Houston, TX 77030 USA
[5] Infect Dis Res Inst, Tampa, FL USA
[6] Interferon Sci, New Brunswick, NJ USA
来源：
GASTROENTEROLOGY | 2000年 / 118卷 / 04期
关键词：
D O I：
10.1016/S0016-5085(00)81854-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
6733
引用
收藏
页码：A1487 / A1487
页数：1
相关论文
共 50 条
  • [41] Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection
    Macias, Juan
    Lopez-Cortes, Luis F.
    Tellez, Francisco
    Recio, Eva
    Ojeda-Burgos, Guillermo
    Jose Rios, Ma
    Rivero-Juarez, Antonio
    Delgado, Marcial
    Rivas-Jeremias
    Pineda, Juan A.
    PLOS ONE, 2015, 10 (12):
  • [42] Differences in outpatient care and treatment utilization for patients with HIV/HCV coinfection, HIV, and HCV monoinfection, a cross-sectional study
    Johnson, Terence L.
    Toliver, Joshua C.
    Mao, Lu
    Oramasionwu, Christine U.
    BMC INFECTIOUS DISEASES, 2014, 14
  • [43] Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection
    Peribanez-Gonzalez, Mario
    da Silva, Mariliza Henrique
    Vilar, Fernando Crivelenti
    Seixas-Santos Nastri, Ana Catharina
    Ferreira, Paulo Abrao
    Focaccia, Roberto
    Mendes Correa, Maria Cassia
    ANNALS OF HEPATOLOGY, 2013, 12 (02) : 228 - 235
  • [44] An open-label, multicenter study of efficacy and safety of peginterferon alfa-2a/ribavirin in HIV/HCV coinfection
    Ortega, E
    Barros, C
    Pulido, F
    Rubio, R
    Garcia, JA
    Aguirrebengoa, K
    Asensi, V
    JOURNAL OF HEPATOLOGY, 2003, 38 : 160 - 160
  • [45] Zone 3 hepatocyte giant cell transformation in the setting of HCV/HIV coinfection
    Micchelli, STL
    Boitnott, JK
    Torbenson, MS
    MODERN PATHOLOGY, 2006, 19 : 277A - 277A
  • [46] Zone 3 hepatocyte giant cell transformation in the setting of HCV/HIV coinfection
    Micchelli, STL
    Boitnott, JK
    Torbenson, MS
    LABORATORY INVESTIGATION, 2006, 86 : 277A - 277A
  • [47] Interleukin-2 therapy as novel approach for the treatment of HIV/HBV and HIV/HCV coinfection.
    Schlaak, JF
    Radecke, K
    HEPATOLOGY, 1998, 28 (04) : 507A - 507A
  • [48] Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection
    Zarebska-Michaluk, Dorota
    Jaroszewicz, Jerzy
    Parfieniuk-Kowerda, Anna
    Pawlowska, Malgorzata
    Janczewska, Ewa
    Berak, Hanna
    Janocha-Litwin, Justyna
    Klapaczynski, Jakub
    Tomasiewicz, Krzysztof
    Piekarska, Anna
    Krygier, Rafal
    Citko, Jolanta
    Tronina, Olga
    Dobrowolska, Krystyna
    Flisiak, Robert
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (02)
  • [49] PATIENT, PROVIDER, AND FACILITY CHARACTERISTICS OF HCV ANTIVIRAL TREATMENT AMONG US VETERANS WITH HCV-HIV COINFECTION
    Kramer, Jennifer R.
    Kanwal, Fasiha
    Giordano, Thomas P.
    Richardson, Peter
    Petersen, Laura
    El-Serag, Hashem B.
    HEPATOLOGY, 2008, 48 (04) : 359A - 359A
  • [50] Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV/HCV coinfection
    Olea, Antonio, Jr.
    Grochowski, Janet
    Luetkemeyer, Anne F.
    Robb, Valerie
    Saberi, Parya
    INTEGRATED PHARMACY RESEARCH AND PRACTICE, 2018, 7 : 105 - 111
12345